China's Neptunus Interlong H1 revenue falls

Shenzhen Neptunus Interlong Bio-technique

25/08/2026 13:41

Overview
China pharma and medical device firm's H1 revenue fell year-over-year
Net income attributable to owners declined for the half-year period
No interim dividend declared for the reporting period

Outlook
Company did not provide specific financial outlook

Result Drivers
RECEIVABLE IMPAIRMENTS - Co recorded net impairment losses on trade and other receivables during the period
HIGH OPERATING EXPENSES - Administrative and operating expenses remained elevated, contributing to lower profit

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 436.20 mln
 
H1 Net Income Attributable
 
RMB 7 mln
 

Reuters Recommended Reads
Aug 24 - China's InnoCare Pharma H1 revenue surges, partly on orelabrutinib growth
Aug 24 - China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Aug 24 - China's Peijia Medical H1 revenue jumps on transcatheter valve therapeutics growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-25/9ff5affc-785f-4ac8-8892-6d072f843f3c.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)